The mechanisms for the development of metastatic skeletal lesion and the role of N-bisphosphonates in its therapy

Voloznev L.V.

doi:https://doi.org/

Voloznev L.V.

Kafedra radiobiologii i biofiziki FGBOU VPO "Moskovskaia gosudarstvennaia akademiia veterinarnoĭ meditsiny i biotekhnologii im. K.I. Skriabina"

The mechanisms for the development of metastatic skeletal lesion and the role of N-bisphosphonates in its therapy

Authors:

Voloznev L.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(1): 73‑77

Read: 15469 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Voloznev LV. The mechanisms for the development of metastatic skeletal lesion and the role of N-bisphosphonates in its therapy. P.A. Herzen Journal of Oncology. 2013;2(1):73‑77. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Cost-effectiveness analysis of denosumab therapy in adults with solid tumors and bone metastases (in Russian healthcare). Medical Technologies. Assessment and Choice. 2024;(4):74-89

Abstract:

Metastatic bone lesions belong to secondary neoplasms, by ranking third in cancer incidence after lung and liver metastases. The mechanisms underlying a bone lesion are complex and result from the interaction between both the tumor and the bone system. The mechanism of action of bisphosphonates and the pathogenetic mechanisms of bone resorptive processes due to the influence of metastatic cells are shown. An understanding of a metastatic lesion process allows one to state the considerable role of using N-bisphosphonates and to introduce them into clinical practice to improve the results of treatment and quality of life in patients.

Keywords:

metastatic skeletal lesion

zoledronic acid

N-bisphosphonates

Authors:

Voloznev L.V.

Kafedra radiobiologii i biofiziki FGBOU VPO "Moskovskaia gosudarstvennaia akademiia veterinarnoĭ meditsiny i biotekhnologii im. K.I. Skriabina"

Close metadata

References:

Karpenko V.Yu. Khirurgicheskoe lechenie metastaticheskogo porazheniya dlinnykh trubchatykh kostei kak etap kombinirovannoi terapii: Avtoref. dis. ... kand. med. nauk. M.; 2005.
Pavlenko N.N., Korshunov G.V., Popova T.N., Zhandarova L.F., Ekaterinushkin D.A., Matveeva O.V. i dr. Metastaticheskoe porazhenie kostnoi sistemy. Sibirskii onkologicheskii zhurnal. 2011; 4 (46): 47-9.
Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J. Support. Oncol. 2004; 2 (3): 205-20.
Zhi-ye Du, Jie Zang, Xiao-dong Tang, Wei Guo. Experts' agreement on therapy for bone metastases. Orthopaed. Surg. 2010; 2 (4): 241-53.
Moiseenko V.M. Palliativnoe lechenie bol'nykh solidnymi opukholyami s metastaticheskim porazheniem kostei. Prakticheskaya onkologiya. 2001; 1 (5): 33-8.
Pasha S.P., Ternovoi S.K. Radionuklidnaya diagnostika. M.: GEOTAR-Media; 2008.
Teplyakov V.V., Karpenko V.Yu., Aliev M.D. Khirurgicheskoe lechenie bol'nykh s metastaticheskimi porazheniyami dlinnykh kostei. Vestnik travmatologii i ortopedii. 2007; 4: 73-7.
Coleman R.E., Paterson A.H., Conte P.F. et al. Advances in the management of metastatic bone disease. The Breast. 1994; 3: 181-5.
Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889; 1: 99-101.
Bishayee A., Rao D.V., Srivastava C. et al. Marrow-sparing effects of 117m Sn (4+) diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J. Nucl. Med. 2000; 41: 2043-50.
Volkov N.M. Fiziologiya metabolizma kostnoi tkani i mekhanizm razvitiya metastazov v kosti. Prakticheskaya onkologiya. 2011; 12 (3): 97-102.
Yoshino K., Tanabe M., Ohnuma N., Takahashi H. Histopathologic analysis of bone marrow and bone metastasis in murine neuroblastoma. Clin. Exp. Metastasis. 1996; 14: 459-65.
Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I. et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell. Biol. 2003; 160: 267-77.
Soharaa Y., Shimada H., DeClerck Y.A. Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Letters. 2005; 228: 203-9.
Ewing J. Neoplastic diseases: A treatise on turnours. 3rd ed. Philadelphia: WB Saunders Co; 1928: 77-89.
Li Jiarong, Karaplis Andrew C., Huang Dao C., Siegel Peter M., Camirand Anne, Yang Xian Fang et al. PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J. Clin. Invest. 2011; 121 (12): 4655-69.
Kondrat'ev V.B., Martynyuk V.V., Li L.A. Metastazy v kosti: oslozhnennye formy, giperkal'tsiemiya, sindrom kompressii spinnogo mozga, medikamentoznoe lechenie. Prakticheskaya onkologiya. 2000; 2 (6): 41-5.
Eriksen E.F. Cellular mechanisms of bone remodeling. Rev. Endocr. Metab. Disord. 2010; 11 (4): 219-27.
Eriksen E.F. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr. Rev. 1986; 7 (4): 379-408.
Eriksen E.F., Hodgson S.F., Eastell R. et al. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Miner. Res. 1990; 5 (4): 311-9.
Murthy R.K., Morrow P.K., Theriault R.L. Bone biology and the role of the RANK ligand pathway. Oncology (Williston.Park). 2009; 23 (14, Suppl. 5): 9-15.
Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001; 142 (12): 5050-5.
Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2002; 2 (8): 585-93.
Roodman D.G. Mechanisms of bone metastasis. N. Engl. J. Med. 2004; 350: 1655-64.
Clines G.A., Guise T.A. Mechanisms and Treatment for Bone Metastases. Clin. Adv. Hematol. Oncol. 2004; 2 (5): 295-302.
Saad F., Schulman C.C. Role of bisphosphonates in prostate cancer. Eur. Urol. 2004; 45: 26-34.
Zhang J., Dai J., Qi Y. et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 2001; 107: 1235-44.
Nelson J.B., Hedican S.P., George D.J. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1995; 1: 944-9.
Lipton A. Management of metastatic bone disease and hypercalcemia of malignancy. Am. J. Cancer. 2003; 2 (6): 427-38.
Berruti A., Dogliotti L., Tucci M., Tarabuzzi R., Fontana D., Angeli A. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J. Urol. 2001; 166: 2023-31.
Baczyk M., Baczyk E., Czepczynski R., Sowinski J. Sr-89 and palmidronate in palliative treatment of osteoblasticosteolytic breast cancer bone metastases. World J. Nucl. Med. 2002; 1 (Suppl. 2): S131-2.
Coxon F.P., Thompson K., Rogers M.J. Recent advances in understanding the mechanism of action of bisphosphonates [review]. Curr. Opin. Pharmacol. 2006; 6 (3): 307-12.
Amin D., Cornell S.A., Perrone M.H. et al. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as apotent inhibitor of squalene synthase. Arzneimittel Forschung. 1996; 46: 759-62.
Russell R.G.G., Watts N.B., Ebetino F.H. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733-59.
Apolikhin O.I., Sivkov A.V., Oshchepkov V.N., Keshishev N.G., Kostin I.E., Rabinovich E.Z. Effektivnost' zoledronovoi kisloty u bol'nykh s kostnymi metastazami raka predstatel'noi zhelezy. Andrologiya i genital'naya khirurgiya. 2009; 2: 117.
Storozhakova A.E., Vladimirova L.Yu., Kosinskaya T.M., Abramova N.A., Palii A.L. Opyt primeneniya preparata rezorba v lechenii bol'nykh rakom molochnoi zhelezy s metastazami v kosti. Sibirskii onkologicheskii zhurnal. 2009; Prilozhenie 1: 188.
Toroptsova N.V., Benevolenskaya L.I. Bisfosfonaty i ikh rol' v profilaktike perelomov u zhenshchin s postmenopauzal'nym osteoporozom. Russkii meditsinskii zhurnal. 2008; 16 (10): 680-3.